FDA’s Empower Pharmacy Warning Letter: What It Means for Your Compounded Tirzepatide
Released: Last reviewed:
On September 18, 2026 the FDA told one of the country’s largest compounding pharmacies that its tirzepatide and semaglutide looked like copies of the approved drugs. Here is what the letter says, what it does not do, and the five things to check if you take compounded tirzepatide.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP · Sources cited at the end · Prices read on each provider’s own page October 14, 2026.
The FDA’s September 18, 2026 warning letter to Empower Pharmacy (Houston, Texas) says its compounded tirzepatide-niacinamide and semaglutide-B12 appeared to be “essentially copies” of FDA-approved drugs and cites sterile-production problems. It is not a ban on compounded tirzepatide and not a recall. If your vials come from Empower, ask your telehealth program in writing which pharmacy will fill your next order and why.
What the FDA letter says
Warning Letter 738238 is dated September 18, 2026 and was posted on FDA.gov on September 22. It is addressed to Empower Clinic Services, LLC, doing business as Empower Pharmacy, for its 503A pharmacy in Houston. FDA investigators inspected the site from November 3 to 14, 2025, and the letter cites products made between July and October 2025:
- tirzepatide/niacinamide 17/2 mg/mL (4 mL) and 8/2 mg/mL (2.5 mL);
- semaglutide/cyanocobalamin 5/0.5 mg/mL (1 mL).
The letter makes two separate findings.
1. “Essentially copies.” A 503A pharmacy may not regularly or in inordinate amounts compound drugs that are essentially copies of commercially available approved drugs. There is an exception when a prescriber decides that a change makes a significant difference for that specific patient. The FDA wrote that the products “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products.” It said some prescriptions carried no prescriber determination at all. Others carried significant-difference statements “repeated verbatim across many records” that “may be pre-generated for selection by the prescriber.” Given the volume produced, the FDA said, the claimed differences appeared to be “pretextual.” The products therefore lost their 503A exemptions. The FDA treats them as unapproved new drugs and as misbranded.
2. Insanitary conditions. Separately, the FDA cited sterile-production problems:
- Smoke studies did not show unidirectional airflow in the ISO 5 area under dynamic conditions.
- Media fills were not run under the most challenging conditions.
- A media-fill summary’s vial count did not match the underlying records.
The agency concluded there was “a lack of assurance” that the firm could produce drugs aseptically at the facility. It also noted that this provision applies whether or not a product meets the 503A conditions.
Empower had 15 working days to respond. A company spokesperson said it had “already remediated many of the issues outlined in the Warning Letter.” The FDA has sent Empower letters before, in October 2021 and April 2025.
Why adding B12 or niacinamide does not settle the question
Many compounded GLP-1 programs add a vitamin, such as B12, B6, niacinamide or glycine, to the active ingredient. Readers often take the additive as the legal reason the product is not a copy. The letter and the lawyers who have analyzed it say the additive alone does not establish a significant difference. What counts is a documented, patient-specific clinical judgment by the prescriber. A checkbox chosen from a menu, or the same sentence pasted into thousands of prescriptions, is the pattern the FDA called out. Under the FDA’s compounding guidance, “essentially a copy” can include the same active ingredient at the same, a similar or an easily substitutable strength.
What the letter does not do
- It is not a ban. Compounded tirzepatide made for an individual patient with a real, documented clinical reason is still legal under section 503A.
- It is not a recall. A warning letter asks a company to fix violations. It does not by itself pull product from patients’ refrigerators. If the FDA or Empower announces a recall, it will appear on FDA’s recalls page. We will add it to our news ledger.
- It does not finalize the 503B proposal. On April 30, 2026 the FDA proposed keeping tirzepatide, semaglutide and liraglutide off the 503B bulks list. The comment period closed July 30, 2026. As of October 14, 2026 no final decision had been published (our explainer).
The direction is clear even so. The FDA is moving from warning telehealth marketers to examining how pharmacies and prescribers justify each compounded GLP-1 order. Programs that depend on a single high-volume pharmacy carry more supply risk than programs that name several.
The 2024–2026 timeline in one table
| Date | Event |
|---|---|
| Dec 19, 2024 | FDA confirms the tirzepatide shortage is resolved; enforcement grace periods for compounders follow |
| Feb 18 / Mar 19, 2025 | Grace periods end for 503A pharmacies and 503B outsourcing facilities |
| Nov 3–14, 2025 | FDA inspects Empower’s Houston 503A pharmacy |
| Apr 30, 2026 | FDA proposes keeping tirzepatide, semaglutide and liraglutide off the 503B bulks list |
| Jul 30, 2026 | Comment period on that proposal closes |
| Sep 18, 2026 | Warning letter to Empower (posted Sep 22) |
| Oct 14, 2026 | No final 503B decision published |
Which programs name Empower?
Most telehealth programs do not name their pharmacy on the sales page, so you often learn it from the label on your first box. Of the programs in our open dataset, NexLife’s microdose program pages list Empower among five dispensing pharmacies, with Absolute, Hallandale, Red Rock and Strive. Fulfillment depends on your location, the provider’s direction and other factors. NexLife’s standard tirzepatide and semaglutide plan pages, read October 14, 2026, name three other pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA). Embody and SnagRx name Red Rock, Health Warehouse, Precision Medicine and Triad Rx. Each pharmacy’s profile is in our pharmacy directory, including Empower.
Five things to check this week if you take compounded tirzepatide
- Read the label. The dispensing pharmacy’s name, address and license number are on the vial label or pharmacy insert. If it says Empower, keep the box.
- Ask your program in writing which pharmacy will fill your next order. Also ask whether it has changed anything since September 22. A program that can answer in one message is a better sign than one that cannot.
- Do not stop or change doses on your own. If a refill is delayed or the pharmacy changes, ask your prescriber how to restart. Restarting at a full dose after two or more missed weeks raises the risk of nausea and vomiting.
- Check the beyond-use date and storage. Use nothing past its beyond-use date or left unrefrigerated longer than the label allows. Report side effects or quality concerns to FDA MedWatch.
- Price your fallback. If you would switch, know the numbers in the table below before a supply gap forces the decision.
What switching would cost (October 14, 2026)
| Option | Monthly | Basis | Pharmacy named? |
|---|---|---|---|
| NexLife (compounded) | $139 | 12-month plan charged monthly ($169 month to month); coaching and nutrition plan included | Yes: three on plan pages |
| Collective (compounded) | $86 all-in | $69 plus a $199 yearly membership | No |
| Embody (compounded) | $119 | 12-month supply paid at once ($1,428), all payments final | Yes: four |
| Zepbound via LillyDirect (FDA-approved) | $299–$449 | $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg with refills within 45 days ($499–$699 otherwise) | Lilly |
| Foundayo pill via LillyDirect (FDA-approved, orforglipron) | $149–$299 | By dose; 2.5 mg and 5.5 mg prices reduced through Dec 31, 2026 | Lilly |
Medicare Part D enrollees who qualify for the GLP-1 Bridge pay $50 a month for brand GLP-1s through 2027. For the full year-one math on brand versus compounded at every dose, see Zepbound vs compounded tirzepatide: 12-month cost at every dose.
How this affects our rankings
Our v4.1 methodology gives 15 of 100 points to pharmacy transparency: whether a program names the pharmacies that fill its prescriptions, and whether those pharmacies hold clean records. We have added the Empower letter to its pharmacy profile. Any program that fills through Empower will be re-checked on that category at its next scheduled re-read, NexLife’s microdose program included. If a score changes, the change and the reason will be logged on the verification queue and in the news ledger.
Frequently asked questions
Is compounded tirzepatide illegal now?
No. Section 503A still allows a pharmacy to compound tirzepatide for an individual patient when the prescriber documents a real clinical difference from the approved product. What the FDA challenged is high-volume production with copy-paste justifications.
Should I throw away vials from Empower?
Not on the strength of the letter alone; it is not a recall. Check the beyond-use date and storage, keep the label, and ask your prescriber and program before changing anything. If a recall is announced, follow its instructions.
Does the B12 in my compounded semaglutide make it legal?
Not by itself. The FDA and the lawyers who have analyzed the letter say an additive does not establish a significant difference. The prescriber’s patient-specific determination is what matters.
Will my telehealth program switch pharmacies?
Many programs already use several pharmacies and route orders by state. Ask yours in writing which pharmacy will fill your next order. Ask too whether the price, dose form or additive will change.
Is brand Zepbound worth the extra cost?
Zepbound is FDA-approved and made under cGMP, which compounded products are not. Self-pay through LillyDirect it costs $299–$449 a month by dose, against $86–$169 for the compounded programs above. Whether that is worth it is a decision for you and your clinician.
Sources
- FDA Warning Letter 738238 to Empower Clinic Services, LLC dba Empower Pharmacy, September 18, 2026 (posted September 22, 2026), as summarized in Buchanan Ingersoll & Rooney and Vanguard Laboratory.
- BioSpace: FDA slams GLP-1 compounder (September 2026).
- Federal Register, June 26, 2026: extension of comment period (91 FR 38719) on the proposal published May 1, 2026 (91 FR 23431, Docket FDA-2018-N-3240).
- Lilly: Zepbound coverage and savings (read October 14, 2026).
- LillyDirect: Foundayo (read October 14, 2026).
- FDA: concerns with unapproved GLP-1 drugs used for weight loss.
Not medical advice. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. Talk with a licensed clinician before starting, stopping or switching treatment.